Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Barinthus Biotherapeutics plc

Healthcare US BRNS

0.6978USD
0.04(5.41%)

Last update at 2026-06-22T20:00:00Z

Day Range

0.670.77
LowHigh

52 Week Range

0.512.91
LowHigh

Fundamentals

  • Previous Close 0.66
  • Market Cap24.10M
  • Volume31203
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-55.22300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.13300M
  • Diluted EPS TTM-1.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -68.79339M -61.22700M -76.81860M 0.85M -51.14000M
Minority interest 0.03M 0.11M 0.08M 0.02M -0.24700M
Net income -66.42800M -61.07400M -73.63130M 5.34M -50.86500M
Selling general administrative 40.83M 29.67M 39.84M 6.39M 25.12M
Selling and marketing expenses - - 0.15M - -
Gross profit -5.85866M 14.97M 0.80M 44.70M 0.27M
Reconciled depreciation 5.84M 5.80M 5.17M 4.32M 0.60M
Ebit -54.18069M -61.17400M -76.49400M 0.87M -40.88600M
Ebitda -48.33569M -55.37400M -71.06500M 5.19M -40.28400M
Depreciation and amortization 5.84M 5.80M 5.43M 4.32M 0.60M
Non operating income net other - - - - -3.25100M
Operating income -54.19435M -67.97000M -84.23926M -4.04100M -45.22100M
Other operating expenses 54.19M 82.94M 85.04M 47.50M 41.49M
Interest expense 0.05M 0.05M 0.03M 0.02M 2.67M
Tax provision -0.17500M -0.04400M -4.27400M -4.47100M -0.02800M
Interest income 1.96M 2.68M 3.63M 3.10M 0.00200M
Net interest income 1.91M 2.62M 3.59M 3.08M -2.66600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.20500M -0.04400M -3.08692M -4.47100M -0.02800M
Total revenue 0.00000M 14.97M 0.81M 44.70M 0.27M
Total operating expenses 48.34M 82.94M 85.04M 47.50M 41.49M
Cost of revenue 5.86M 5.80M 0.00311M - -
Total other income expense net -14.59904M 6.74M 7.42M 0.57M -7.25400M
Discontinued operations - - - - -
Net income from continuing ops -66.45800M -61.18300M -77.32000M 5.32M -51.11200M
Net income applicable to common shares - - - - -50.86500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 98.17M 160.33M 214.51M 270.20M 280.71M
Intangible assets 14.29M 21.95M 25.11M 28.27M 31.43M
Earning assets - - - - -
Other current assets 6.03M 2.08M 9.91M 8.27M 6.46M
Total liab 23.88M 30.19M 27.51M 27.00M 28.15M
Total stockholder equity 74.21M 130.03M 186.78M 242.90M 252.12M
Deferred long term liab - - - - -
Other current liab 6.25M 7.11M 9.21M - -
Common stock 0.00100M 0.00100M 0.09M - -
Capital stock 0.00100M 0.00100M 0.00100M 0.00100M 0.00100M
Retained earnings -304.09200M -237.66400M -176.59000M -103.24300M -108.58500M
Other liab - - - - -
Good will - 0.00000M 12.21M 12.21M 12.63M
Other assets - - - - -
Cash 70.46M 110.66M 142.09M 194.38M 214.05M
Cash and equivalents - - - - -
Total current liabilities 10.02M 15.66M 12.60M 12.24M 11.16M
Current deferred revenue 1.40M 1.74M - - -
Net debt -59.17500M -98.65500M -129.11400M - -
Short term debt 2.02M 1.92M 1.78M - -
Short long term debt - - - - 0.16M
Short long term debt total 11.28M 12.01M 12.98M - -
Other stockholder equity 393.94M 393.56M 386.60M - -
Property plant equipment - - - - -
Total current assets 77.79M 125.74M 156.91M 213.04M 226.76M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 1.30M 13.00M 4.91M 5.85M 0.02M
Long term debt - - - - -
Inventory - - 0.00000M - -
Accounts payable 0.35M 2.47M 1.60M 3.75M 2.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -15.73100M -25.86800M -23.31500M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.93M 0.88M 0.88M 0.98M 0.80M
Deferred long term asset charges - - - - -
Non current assets total 20.38M 34.59M 57.60M 57.16M 53.95M
Capital lease obligations 11.28M 12.01M 12.98M 8.77M 7.06M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.89200M -6.15200M -5.75000M -12.91200M
Change to liabilities - - - - 0.89M
Total cashflows from investing activities 0.42M -0.89200M - - -12.91200M
Net borrowings - - - - -
Total cash from financing activities 0.00200M 2.16M 1.87M 0.33M 222.74M
Change to operating activities - - - - -4.14600M
Net income -66.45800M -61.18300M -73.44700M 5.32M -51.11200M
Change in cash -40.54800M -29.69000M -52.29500M -19.66900M 170.79M
Begin period cash flow 112.40M 142.09M 194.38M 214.05M 43.27M
End period cash flow 71.85M 112.40M 142.09M 194.38M 214.05M
Total cash from operating activities -47.97900M -28.94000M -50.92500M -14.43100M -32.58300M
Issuance of capital stock 0.00000M 2.16M 2.41M 0.48M 228.01M
Depreciation 5.84M 5.80M 5.43M 4.32M 0.60M
Other cashflows from investing activities -0.00106M - - - -11.76600M
Dividends paid - - - - -
Change to inventory - - - -0.64800M -4.14600M
Change to account receivables 6.42M -2.34500M 5.80M -5.83300M 0.56M
Sale purchase of stock - - - - 100.60M
Other cashflows from financing activities -0.00000M 2.16M -0.16300M -5.75000M 119.97M
Change to netincome - - - - 23.95M
Capital expenditures 0.04M 0.89M 5.41M 6.14M 1.15M
Change receivables - - - - 0.56M
Cash flows other operating - - - - -7.47500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 177.25M
Change in working capital -0.35984M 2.60M 6.17M -5.52400M -7.17800M
Stock based compensation 0.47M 4.71M 5.05M 9.88M 16.49M
Other non cash items 12.70M 19.18M 8.94M -24.09100M 8.74M
Free cash flow -48.01600M -29.83200M -56.33800M -20.56900M -33.72900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BRNS
Barinthus Biotherapeutics plc		 0.04 5.41% 0.70 - - 2.16 0.33 0.62 -6.6662
NVO
Novo Nordisk A/S		 2.69 6.23% 45.88 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.60 3.69% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 15.16 3.36% 466.79 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.56 0.42% 612.50 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.

Barinthus Biotherapeutics plc

20400 Century Boulevard, Germantown, MD, United States, 20874

Key Executives

Name Title Year Born
Mr. William J. Enright MBA CEO & Director 1962
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 1979
Mr. Graham Griffiths Chief Business Officer 1980
Ms. Sarah Gilbert Co-Founder NA
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor NA
Ms. Gemma Brown CFO & Company Secretary 1991
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations NA
Bernie McDonald Head of IP NA
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies NA
Mr. William James Enright MBA CEO, Director, Secretary & Principal Financial Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions